<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04567225</url>
  </required_header>
  <id_info>
    <org_study_id>20-903</org_study_id>
    <nct_id>NCT04567225</nct_id>
  </id_info>
  <brief_title>Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management</brief_title>
  <official_title>Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The transition from IV Insulin Infusion (IVII) to Subcutaneous Long-acting insulin injections&#xD;
      in Diabetic Ketoacidosis (DKA) management frequently results in rebound hyperglycemia,&#xD;
      particularly if there are high insulin requirements that can adversely affect the DKA&#xD;
      recovery, increase Length Of Stay (LOS), morbidity, and mortality. Investigators propose a&#xD;
      prospective, open-label, intervention, non-randomized, controlled study to test the&#xD;
      hypothesis that an insulin glargine dose of 0.4 Units/kg early administered (within four&#xD;
      hours) of IVII initiation in DKA management in adult would be effective and safe in&#xD;
      shortening the time to anion gap closure comparing to the standard practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopped after internal review&#xD;
  </why_stopped>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Actual">August 27, 2021</completion_date>
  <primary_completion_date type="Actual">August 27, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to anion gap closure</measure>
    <time_frame>Participants monitored from hospital admission to discharge, an average of 5 days</time_frame>
    <description>Measured in hours from starting insulin infusion till anion gap ≤ 12 milliequivalent/Liter (mEq/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of stay</measure>
    <time_frame>Participants monitored from hospital admission to discharge, an average of 5 days</time_frame>
    <description>The time, in days, from the patient admission to the hospital till discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>Participants monitored from hospital admission to discharge, an average of 5 days</time_frame>
    <description>The time, in hours, from the patient admission to the ICU till transfer to regular nursing floor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total IV insulin infusion dose</measure>
    <time_frame>Participants monitored from hospital admission to discharge, an average of 5 days</time_frame>
    <description>the total amount of insulin infusion, by International Unit, has been received by the patient during the DKA treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of transitional failure</measure>
    <time_frame>up to 24 hours after IVII discontinuation</time_frame>
    <description>Defined as the recurrence of DKA (BG ≥ 250 mg/dl, Anion Gap &gt; 12 milliequivalent/Liter (mEq/L), and positive Ketones in serum or urine) after initial IV insulin infusion (IVII) discontinuation within 24 hours and requiring re-initiating the IVII</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hyperglycemia</measure>
    <time_frame>up to 24 hours after initial Insulin Glargine dose</time_frame>
    <description>Incidence of hyperglycemia (&gt; 180 mg/dL) after IVII discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycemia</measure>
    <time_frame>up to 24 hours after initial Insulin Glargine dose</time_frame>
    <description>Incidence of hypoglycemia (defined as ≤ 70 mg/dL, &lt;54 mg/dL, &lt;40 mg/dl) after IVII discontinuation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Diabetic Ketoacidosis</condition>
  <condition>Type 1 Diabetes</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Early Glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All consecutive adult patients getting admitted to Medical ICU and meet the inclusion criteria and accepted to receive insulin glargine early as per the protocol. They will receive insulin glargine 0.4 unit/kg within 4 hours from initiating the IV Insulin Infusion, as per the Cleveland Clinic DKA protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard practice (Late Glargine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Retrospective, prespecified and matched sample of consecutive adults who admitted to the same Medical ICU with a diagnosis of DKA in the period between January 1st 2019 till the Institutional Review Board (IRB) approval date and didn't receive basal insulin before Anion Gap closure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine</intervention_name>
    <description>A dose of insulin glargine, 0.4 unit/kg, will be given within 4 hours from initiating the IV Insulin Infusion</description>
    <arm_group_label>Early Glargine</arm_group_label>
    <other_name>lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine</intervention_name>
    <description>A historical retrospective control group for the adult patients admitted to the same ICU with a diagnosis of DKA and received insulin glargine after anion gap closure.</description>
    <arm_group_label>Standard practice (Late Glargine)</arm_group_label>
    <other_name>lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IV insulin infusion</intervention_name>
    <description>Continuous weight based IV insulin infusion as per Cleveland Clinic DKA Protocol</description>
    <arm_group_label>Early Glargine</arm_group_label>
    <arm_group_label>Standard practice (Late Glargine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IV fluid and electrolytes replacement</intervention_name>
    <description>The IV fluid and electrolytes replacement will be left to the treating physician's discretion. IV fluid to contain dextrose to keep Target Blood Glucose 150 - 200 mg/dl during the DKA management and 140 - 180 mg/dl after DKA resolution.</description>
    <arm_group_label>Early Glargine</arm_group_label>
    <arm_group_label>Standard practice (Late Glargine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Meet DKA definition (BG ≥ 250 mg/dl, Anion Gap &gt; 12 mEq/L, and positive Ketones in&#xD;
             serum or urine)&#xD;
&#xD;
          -  Having the capacity to sign Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  IV insulin infusion was initiated for more than 4 hours.&#xD;
&#xD;
          -  Persistent hypotension (SBP&lt;80 mmHg despite receiving 1000cc normal saline).&#xD;
&#xD;
          -  Require Vasopressor&#xD;
&#xD;
          -  Acute Coronary Syndrome&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  End-stage renal disease&#xD;
&#xD;
          -  Unwilling to consent to participate in the trial&#xD;
&#xD;
          -  Currently under police custody&#xD;
&#xD;
          -  Transferred from another hospital&#xD;
&#xD;
          -  Require emergent surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed Al jaghbeer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Fairview Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Realsen J, Goettle H, Chase HP. Morbidity and mortality of diabetic ketoacidosis with and without insulin pump care. Diabetes Technol Ther. 2012 Dec;14(12):1149-54. doi: 10.1089/dia.2012.0161. Epub 2012 Sep 25. Review.</citation>
    <PMID>23009106</PMID>
  </reference>
  <reference>
    <citation>Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009 Jul;32(7):1335-43. doi: 10.2337/dc09-9032. Review.</citation>
    <PMID>19564476</PMID>
  </reference>
  <reference>
    <citation>Bunn S, Halm M. Long-Acting Insulin on the Road to Recovery With Diabetic Ketoacidosis. Am J Crit Care. 2016 May;25(3):277-80. doi: 10.4037/ajcc2016681. Review.</citation>
    <PMID>27134235</PMID>
  </reference>
  <reference>
    <citation>Hsia E, Seggelke S, Gibbs J, Hawkins RM, Cohlmia E, Rasouli N, Wang C, Kam I, Draznin B. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J Clin Endocrinol Metab. 2012 Sep;97(9):3132-7. doi: 10.1210/jc.2012-1244. Epub 2012 Jun 8.</citation>
    <PMID>22685233</PMID>
  </reference>
  <reference>
    <citation>Savage MW, Dhatariya KK, Kilvert A, Rayman G, Rees JA, Courtney CH, Hilton L, Dyer PH, Hamersley MS; Joint British Diabetes Societies. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet Med. 2011 May;28(5):508-15. doi: 10.1111/j.1464-5491.2011.03246.x.</citation>
    <PMID>21255074</PMID>
  </reference>
  <reference>
    <citation>Doshi P, Potter AJ, De Los Santos D, Banuelos R, Darger BF, Chathampally Y. Prospective randomized trial of insulin glargine in acute management of diabetic ketoacidosis in the emergency department: a pilot study. Acad Emerg Med. 2015 Jun;22(6):657-62. doi: 10.1111/acem.12673. Epub 2015 May 25.</citation>
    <PMID>26013711</PMID>
  </reference>
  <reference>
    <citation>Houshyar J, Bahrami A, Aliasgarzadeh A. Effectiveness of Insulin Glargine on Recovery of Patients with Diabetic Ketoacidosis: A Randomized Controlled Trial. J Clin Diagn Res. 2015 May;9(5):OC01-5. doi: 10.7860/JCDR/2015/12005.5883. Epub 2015 May 1.</citation>
    <PMID>26155506</PMID>
  </reference>
  <reference>
    <citation>Shankar V, Haque A, Churchwell KB, Russell W. Insulin glargine supplementation during early management phase of diabetic ketoacidosis in children. Intensive Care Med. 2007 Jul;33(7):1173-1178. doi: 10.1007/s00134-007-0674-3. Epub 2007 May 17.</citation>
    <PMID>17508198</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Mohammed Al-Jaghbeer</investigator_full_name>
    <investigator_title>Clinical Assistant professor and Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Ketosis</mesh_term>
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Diabetic Ketoacidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual subject results will not be shared with those involved in the prospective arm</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

